Validated Stability indicating Spectrophotometric Method for the Determination of Acetazolamide in Dosage Forms through Complex Formation with Palladium (II)

M. I. Walash, A. El-Brashy, N. El-Enany, M. E. K. Wahba

Department of Analytical Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt

ABSTRACT

A simple and sensitive spectrophotometric method was developed for the determination of acetazolamide (ACM) in pure form and pharmaceutical preparations. The proposed method is based on the complex formation of acetazolamide with Palladium (II) chloride in acetate buffer pH5.4 and measuring the absorbance at 308 nm. The absorbance-concentration plot was rectilinear over the concentration range of 5-70 µg/ml with a minimum detection limit (LOD) of 0.98 µg/ml, limit of quantification (LOQ) of 2.96 µg/ml, and a molar absorptivity \( \xi = 2.7 \times 10^3 \) L/mol.cm. The factors affecting the absorbance of the formed complex were carefully studied and optimized. The composition of the complex as well as its stability constant was also investigated. The proposed method was applied for the determination of acetazolamide in its tablets and the results obtained were favorably compared with those obtained using the official method. A proposal of the reaction pathway was postulated. (Int J Biomed Sci 2010; 6 (2): 141-149)

Keywords: spectrophotometry; Palladium (II); complexation; acetazolamide

INTRODUCTION

Acetazolamide (ACM) is chemically named according to the IUPAC system as 5-acetamido-1, 3, 4-thiadiazole-2-sulphonamide; N-(5-sulphamoyl-1, 3, 4, thiadiazole-2-yl) acetamide (Fig. 1). It acts on the central nervous system to retard the abnormal, paroxysmal, and excessive discharge from CNS neurons (I). Various methods were reported for its determination either per se or in pharmaceutical preparations and biological fluids including: spectrophotometry (2-6), HNMR (4), electrochemical methods (7, 8), and HPLC (9-27). The British Pharmacopoeia (BP) (28) recommended potentiometric determination of ACM in dimethylformamide using ethanolic solution of sodium hydroxide as a titrant, while the United States Pharmacopoeia (USP) method (29) recommended a spectrophotometric measurement of the acidic solution of the pharmaceutical preparation at 265 nm. Since the hydrolysis product 5-amino-1, 3, 4 - thiadiazole-2-sulfonamide also absorbs light at the same wavelength (265 nm); the USP method therefore cannot be considered as a stability indica-

Figure 1. Structural formula of acetazolamide.
cating assay (29). A good guide to the work published for this compound up to 1993 is found in the monograph written by Parasrampuria on its Analytical Profiles of Drug Substances and Excipients (30).

The use of Palladium (II) chloride as a complexing agent for the determination of many compounds of pharmaceutical interest is fairly wide. The complexes of palladium (II) ions bear the advantage of being water-soluble, and hence do not necessitate any extraction procedures. Several compounds of pharmaceutical interest were determined through this approach such as: captopril (31), gliclazide (32), some thiazole cephalosporins (33), norfloxacine and ciprofloxacine (34), phenothiazines (35-37), timonacic acid (38), and thiocotic acid (39).

The molecular structure of ACM is characterized by the presence of sulfur atom which is susceptible to complexation with palladium (II) and this initiated the present study. Up to the present time, nothing has been published concerning the complex formation between ACM and Pd (II).

Since the proposed method proved to be a stability indicating one, it could be a useful guide to indicate the presence of acetazolamide in its stable intact form keeping in mind that the hydrolyzed form of the drug has a little if any pharmacological activity.

**EXPERIMENTAL PROCEDURES**

**Apparatus**

The spectrophotometric measurements were established using Shimadzu UV-visible 1601 recording spectrophotometer (P/N 206-67001). Recording range, 0-1.0; wavelength, 308 nm.

**Materials and reagents**

All reagents and solvents were of Analytical Reagent grade. Acetazolamide (ACM) was kindly provided by Chemical Industries Development (CID) pharmaceutical company, Cairo, Egypt. Its purity was checked according to BP (28) and was found to be 98.8%. Cidamex tablets (Batch# 107101), labeled to contain 250 mg of ACM per tablet (CID pharmaceutical company, Cairo, Egypt), and were obtained from commercial sources in the local market. Palladium (II) chloride (Sigma, Milwaukee, WI, USA) was prepared as $5 \times 10^{-3}$ M solution by dissolving about 88.4 mg of PdCl$_2$ in 1 ml hydrochloric acid, with the aid of heat, followed by the addition of boiled water and diluting to 100 ml with distilled water. This solution is stable for two weeks when kept in the refrigerator. Acetate buffer (pH3.6-5.6) (28) was prepared by mixing 0.2 M acetic acid and 0.2 M sodium acetate, the pH has to be checked periodically. Methanol and hydrochloric acid (Merck, Darmstadt, Germany). Potassium chloride, 2 M aqueous solution (BDH, UK), freshly prepared was used.

**Standard solutions**

A stock solution was prepared by dissolving 100.0 mg of ACM in 100 ml of methanol and was further diluted with the same solvent as appropriate. The standard solutions were stable for 7 days when kept in refrigerator.

**Construction of the calibration curve**

Aliquot volumes of ACM standard solution covering the working concentration range cited in Table 1 were transferred into a series of 10 ml volumetric flasks. $2.5 \pm 0.5$ ml of acetate buffer pH5.4, followed by $1 \pm 0.2$ ml of PdCl$_2$ ($5 \times 10^{-3}$ M) solution, and 2 ml of 2 M KCl solution were added, and the volume was completed to the mark with distilled water, and mixed well. The absorbance of the solution was measured at 308 nm against similarly prepared blank solution. Base line correction was carried out to delete any absorbance reading of the blank. The measured absorbance values were plotted against the final concentration of the drug (µg/ml) to get the calibration curve. Alternatively, the corresponding regression equation was derived.

**Procedure for tablets**

Twenty tablets were weighed and pulverized. A weighed quantity of the powder equivalent to 20.0 mg of ACM was transferred into a small conical flask, extracted three successive times each with 30 ml of methanol. The extract was filtered into 100 ml volumetric flask. The conical flask was washed with few mls of methanol. The washings were passed into the same volumetric flask and completed to the mark with the same solvent. Aliquots covering the final concentration range over 10-60 µg/ml were transferred into 10 ml volumetric flasks. The procedures described under “Construction of calibration curve” were followed. The nominal content of the tablets was determined either from the calibration curve or using the corresponding regression equation.

**Procedure for preparation of the alkaline degradation product**

For the kinetic study, aliquot volumes of ACM standard stock solution were transferred to a 25 ml volumetric flask to obtain a final concentration of 400 µg/ml, completed to
the volume with 0.5 M sodium hydroxide, and the solution was left in a boiling water bath. Aliquot volumes of the alkaline solution were transferred to a series of 10 ml volumetric flasks at a fixed time interval (10 minutes), neutralized with 0.5 M hydrochloric acid, and the procedures described under “Construction of the calibration curve” were followed. The absorbance of the resulting hydrolyzed solutions after complexation with Pd (II) was recorded at 308 nm, log a/a-x versus time (minutes) was plotted to get the reaction rate constant and the half life time. Complete degradation was attained by following the same procedure but using 2 M sodium hydroxide, boiling for 2 hours, and neutralizing with 2 M hydrochloric acid.

RESULTS AND DISCUSSION

Transition elements were found to form stable complexes with many ligands containing heteroatoms. There is preference to amines, halogens, cyanides, tertiary phosphines and sulfides. Palladium (II), as one of the transition elements, was reported to form complexes of square or 5-coordinate shape (40). The absorption spectrum of the complex was recorded over the range of 250-500 nm and showed a maximum absorbance at 308 nm which was therefore used for the analytical determination (Fig. 2). The formed complex was found to be stable for more than 90 minutes. The proposed method proved to be 53% more sensitive than previous report (20).

Optimization of the experimental parameters

The spectrophotometric properties of the formed complex as well as the different experimental parameters affecting its development and stability were carefully studied and optimized. Such factors were changed individually while the others were kept constant. These factors include: different types of buffers, pH and volume of the buffer, concentration and volume of palladium (II), temperature, and the effect of different surfactants and different sensitizers.

Effect of pH and buffer solutions

The study was performed using 30 µg/ml of ACM and 5 × 10^-4 M Pd (II) final concentration. The influence of pH of the acetate buffer on the absorbance value of the formed complex was investigated over the pH range 3.6-5.6. Maximum and constant absorbance value was achieved at pH(5.2-5.6) (Fig. 3). Therefore, acetate buffer pH5.4 ± 0.2 was chosen as the optimum pH throughout the study.

Using different buffers such as phosphate buffer or Britton Robinson buffer of pH 5.4 gave the same results; however, acetate buffer was chosen throughout the study because of absence of possible interference produced by other buffers.

Effect of buffer volume

The effect of volume of acetate buffer of pH5.4 on the absorbance value of the formed complex was also studied keeping the concentration of the drug and Pd (II) constant. It was found that increasing the volume of acetate buffer (pH5.4) resulted in a subsequent increase in the absorbance value of the complex up to 2.0 ml, after which it remained constant. Thus 2.5 ± 0.5 ml of acetate buffer of pH5.4 ± 0.2 was chosen as the optimum volume throughout this approach (Fig. 4).

Effect of Palladium (II) concentration

The effect of Pd (II) concentration on the absorbance of the complex was investigated, keeping all the variables
constant, it was found that increasing the concentration of Pd (II) \( (1.0 \times 10^{-3} \text{ M}; 1.0 \text{ ml}) \) resulted in a gradual increase in the absorbance of the complex up to \( (4.0 \times 10^{-3} \text{ M}) \) after which, it remained constant up to \( (6.0 \times 10^{-3} \text{ M}) \); therefore; \( (5.0 \pm 1.0 \times 10^{-3} \text{ M}) \) was used throughout the study (Fig. 5).

**Effect of palladium (II) volume**

Keeping all the variables constant, it was found that increasing the volume of Pd (II) \( (5.0 \times 10^{-3} \text{ M}) \) resulted in a gradual increase in the absorbance value of the complex up to 0.7 ml, after which it remained constant up to 1.25 ml, therefore \( 1.0 \pm 0.2 \text{ ml of } (5.0 \times 10^{-3} \text{ M}) \) was chosen for the study (Fig. 6).

The effect of temperature on the absorbance of the formed complex was studied; the absorbance remained constant when the temperature was raised up to 60°C; the complex was formed instantaneously and remained stable for more than one hour at room temperature.

**Effect of addition order**

The effect of addition order on the absorbance intensity of the system was studied. The results show that the addition order of ACM- acetate buffer -Pd (II) was the best.

**Effect of different surfactants and sensitizers**

The effect of surfactants (at concentrations 2.5, 7.5, 15 µg/ml) on the absorbance value of the formed complex was investigated using different types, such as sodium lauryl sulphate (anionic type), gelatin, and methyl cellulose (nonionic types). Hopefully the surfactant may enhance the absorbance readings of the complex, but unfortunately, it was found that all the studied surfactants had no significant effect on the absorbance of the formed complex. Therefore, for a simple procedure, there is no need to use surfactants. Similarly different sensitizers were tested such as quinine, fluorescein and rhodamine-B. Addition of sensitizers to the reaction mixture was found to enhance the absorbance but with the lack of reproducibility. Therefore, the study was carried out without the addition of sensitizers.

**Analytical performance and application**

The absorbance –concentration plot was found to be linear over the range of 5.0-70 µg/ml (Fig. 7). linear regression analysis of the data gave the following equation:

\[
A = 0.012C + 4.0 \times 10^{-3} \quad (r=0.9997)
\]

where \( A \) is the absorbance in 1-cm cell, \( C \) is the concentration of the drug in µg/ml, and \( r \) is the correlation coefficient.

The limit of quantification (LOQ) was calculated by establishing the lowest concentration that can be measured according to ICH Q2B recommendations (41), and it was found to be 2.96 µg/ml.

LOQ was calculated according to the following equation (41):

\[
LOQ = 10\sigma/S
\]

where \( \sigma \) is the standard deviation of the intercept of the regression line, \( S \) is slope of the calibration curve.
The limit of detection (LOD) was calculated according to the ICH recommendations (41) and it was found to be 0.98 µg/ml.

LOD was calculated according to the following equation (41):

\[ \text{LOD} = 3.3 \sigma/S \]

The proposed method was evaluated by studying the accuracy as percent relative error and precision as percent relative standard deviation (RSD %); the results are abridged in Table 1.

**Validation of the method**

The method was tested for linearity, selectivity, accuracy and precision. By using the above spectrophotometric procedure, a linear regression equation was obtained. The regression plot showed that there was a linear dependence of the absorbance value on the concentration of the drug over the range cited in Table 1. The validity of the proposed method was evaluated by statistical analysis of the regression data regarding the standard deviation of the residual (\(S_{yx}\)), the standard deviation of the intercept (\(S_b\)), and standard deviation of the slope (\(S_a\)) (42). The results are shown in Table 1. The small values of the figures point to the low scattering of the points around the calibration graph and high precision of the proposed method.

**Accuracy**

The accuracy of the proposed method was evaluated by analyzing standard solutions of ACM. The results obtained by the proposed method were favorably compared with those obtained by the USP method (29). The latter involved a spectrophotometric measurement of ACM in 0.1 N hydrochloric acid at 265 nm.

**Table 1. Performance data of the proposed method**

| Parameter                      | Value          |
|--------------------------------|----------------|
| Concentration range(µg/ml)     | 5.0-70         |
| Molar absorptivity \( \varepsilon \) (L mol\(^{-1}\) cm\(^{-1}\)) | \(2.7 \times 10^3\) |
| LOD (µg/ml)                    | 0.98           |
| LOQ (µg/ml)                    | 2.96           |
| Correlation coefficient (\(r\)) | 0.9997        |
| Slope                          | \(1.22 \times 10^{-2}\) |
| Intercept                      | \(1.19 \times 10^{-3}\) |
| \(S_{yx}\) (Standard deviation of the residuals) | \(7.3 \times 10^{-3}\) |
| \(S_b\) (Standard deviation of the slope of the regression line) | \(9.6 \times 10^{-5}\) |
| % Error (RSD%/ \(\sqrt{n}\))  | 0.07           |
| % RSD                          | 0.26           |

**Table 2. Application of the proposed and official method to the determination of ACM in pure form**

| Parameter | Amount taken (µg/ml) | Amount found (µg/ml) | % Found | Official method (29) |
|-----------|----------------------|----------------------|---------|----------------------|
| 10        | 10.12                | 101.20               | 100.99  |
| 20        | 19.98                | 99.90                | 101.05  |
| 30        | 29.86                | 99.51                | 99.95   |
| 40        | 40.08                | 100.20               | 100.66 ± 0.43 |
| 50        | 50.05                | 100.11               |         |

\(\bar{x} \pm SD\) 100.18 ± 0.63

Student’s t test 0.71 (2.78)

Variance ratio F test 2.15 (6.94)

Figures between parentheses are the tabulated t and F values, respectively, at \(p=0.05\) (42).
Statistical analysis (42) of the results obtained by the proposed and official methods using student’s t-test and variance ratio F-test, showing no significant difference between the performance of the two methods regarding the accuracy and precision, respectively (Table 2).

**Table 3.** Validation of the proposed method for the determination of acetazolamide in pure form and in tablets

| Sample                | % Found Repeatability (30.0 µg/ml) | % Found Intermediate precision (40.0 µg/ml) |
|-----------------------|-----------------------------------|-------------------------------------------|
| Acetazolamide (pure form) | 99.90 | 100.51 |
|                       | 100.91 | 99.71 |
|                       | 101.21 | 100.90 |
|                       | 99.62  | 100.32 |
| Mean found %          | 100.40 | 100.40 |
| ±SD                   | 0.77   | 0.50  |
| RSD %                 | 0.77   | 0.50  |
| Cidamex® tablets (acetazolamide 250 mg/tablet) | 99.50 | 98.92 |
|                       | 99.90  | 99.42 |
|                       | 100.21 | 98.71 |
|                       | 99.62  | 99.10 |
| Mean found %          | 99.80  | 99.10 |
| ±SD                   | 0.32   | 0.29  |
| RSD %                 | 0.32   | 0.29  |

**Precision**

**Repeatability.** The repeatability was evaluated through the replicate analysis of ACM samples, pure drug or tablets. The percentage recoveries based on the average of four separate determinations were 100.4 ± 0.77 and 99.8 ± 0.32 for pure form and tablets respectively, thus indicating the high precision of the method (Table 3).

**Intermediate precision.** It was performed through replicate analysis of ACM samples, pure drug or tablets on four successive days. The percentage recoveries based on the average of four separate determinations were 100.4 ± 0.50 and 99.1 ± 0.29 for pure form and tablets respectively. The results are shown in Table 3.

**Robustness of the method.** The robustness of the method adopted was demonstrated by the consistency of the absorbance values with the deliberately minor changes in the experimental parameters such as pH5.4 ± 0.2 produced a constant absorbance value of 0.37 at constant ACM concentration (30 µg/ml); changing the volume of acetate buffer 2.5 ± 0.5 ml (pH5.4), and volume of Pd (II); 1.0 ± 0.2 ml (5.0 × 10⁻³M). These minor changes that may take place during the experimental operation didn’t greatly affect the absorbance value of the reaction product.

**Pharmaceutical applications.** The proposed method was further applied to the determination of ACM in its tablets.

**Selectivity.** Common tablet excipients such as talc, lactose, starch, avisil, and magnesium stearate did not interfere with the assay. The results are abridged in Table 4.

**Table 4.** Application of the proposed and official method for the determination of ACM in its tablets

| Pharmaceutical preparation | Amount taken (µg/ml) | Amount found (µg/ml) | % Found | Official method (29) |
|----------------------------|----------------------|----------------------|---------|----------------------|
| Cidamex® tablet (Acetazolamide 250 mg/tablet) | 10 | 10.01 | 100.10 | 100.23 |
|                            | 20 | 19.97 | 99.85 | 99.65 |
|                            | 30 | 30.04 | 100.13 | 101.54 |
|                            | 40 | 39.96 | 99.90 |
|                            | 50 | 49.67 | 99.34 |
|                            | 60 | 60.14 | 100.23 |
| X ± SD                     | 99.86 ± 0.32 | 100.47 ± 0.35 |
| Student’s t test           | 0.35 (2.31) |
| Variance ratio F test      | 1.19 (5.79) |

Figures between parentheses are the tabulated t and F values, respectively, at p=0.05 (42). Cidamex® is a product of Chemical Industries Development (CID) pharmaceutical company, Cairo, Egypt.
Accuracy

The results of the proposed method were statistically compared with those obtained using the official method. Statistical analysis of the results, using student’s t-test and variance ratio F-test, revealed no significant difference between the performance of the proposed and official methods (29) regarding the accuracy and precision respectively (Table 4).

The formation constant of the reaction product was calculated according to the following equation:

$$K_f = \frac{A / A_m}{[1 - (A/A_m)^{n+1}] c^n n^n}$$

where A and A_m are the observed maximum absorbance and the absorbance obtained from the extrapolation of the two lines obtained from Job’s continuous variation method, respectively; n is the mole fraction of the reagent (the ratio is 2:1 for ACM: Pd (II) respectively) therefore, n=0.3; C is the molar concentration of the drug used in Job’s continuous variation method.

Using the above equation K_f was found to be 0.919 × 10^2.

Also, the Gibbs free energy changes (ΔG) of the reaction were calculated according to the following equation (43):

$$\Delta G = -2.303 \text{ RT log } K_f$$

where R is gas constant= 8.3 joule.degree^(-1).mole^(-1); T is absolute temperature= °C + 273.

Using the above equation ΔG was found to be -1.1 × 10^4 Joule/Mole.

The negative value of ΔG indicates that the reaction is spontaneous.

Stability indication of the method

The proposed method is based mainly on the complex formation between Pd (II) and sulfur atom, imide and sulfonamide groups of the thiadiazole ring of ACM, therefore, upon photoinduced alkaline degradation of the drug, the imide group is decomposed into a primary amine and acetic acid, hence, the complex will no further be formed. Complete degradation of the drug was revealed by the disappearance of the absorption peak of the complex after boiling with 2 M sodium hydroxide for 2 hours. The photoinduced alkaline degradation of ACM followed first order kinetics (Fig. 8) which is in agreement with previous reports (3, 30). The rate constant K=0.0276 min^(-1), and t_½ (0.693/K) was found to be 25 minutes. In acid medium, however, the drug was found to be stable, and this is in agreement

### Table 5. Application of the proposed method for the determination of acetazolamide in the presence of its degradation product

| Parameter | Amount taken of degradation product (µg/ml) | Amount taken of ACM (µg/ml) | Amount found of ACM (µg/ml) | % Found of ACM |
|-----------|------------------------------------------|----------------------------|-----------------------------|---------------|
| 10 µg/ml  | 10                                       | 10.03                      | 100.30                      |               |
| 20        | 20                                       | 20.14                      | 100.70                      |               |
| 30        | 30                                       | 29.94                      | 99.80                       |               |
| 40        | 40                                       | 39.89                      | 99.73                       |               |
| 50        | 50                                       | 50.02                      | 100.04                      |               |
| 20 µg/ml  | 20                                       | 20.06                      | 100.30                      |               |
| 30        | 30                                       | 29.93                      | 99.77                       |               |
| 40        | 40                                       | 39.94                      | 99.85                       |               |
| 50        | 50                                       | 50.07                      | 100.14                      |               |
| 30 µg/ml  | 10                                       | 10.14                      | 101.40                      |               |
| 20        | 20                                       | 20.06                      | 100.30                      |               |
| 30        | 30                                       | 30.25                      | 100.83                      |               |
| 40        | 40                                       | 40.09                      | 100.23                      |               |
| 50        | 50                                       | 49.96                      | 99.92                       |               |

X ± SD

Student’s t test 100.11 ± 0.39
Variance ratio 0.93 (2.78)
F test 1.22 (6.94)

X ± SD

Student’s t test 100.29 ± 0.66
Variance ratio 0.53 (2.78)
F test 2.36 (6.94)

X ± SD

Student’s t test 100.65 ± 0.61
Variance ratio 0.99 (2.78)
F test 2.01 (6.94)

Figures between parentheses are the tabulated t and F values, respectively, at p=0.05 (42).
with reports which state that the drug has a maximum stability at pH 4 (3, 30).

Upon exposure of a methanolic solution of ACM to Deuterium lamp with \( \lambda \) 254 nm for different time intervals (up to 180 minutes), it was found that only 30% of the drug has been decomposed. The degradation product showed no interference with the assay of ACM as revealed by the high accuracy and precision of the proposed method. The results are abridged in Table 5.

**Mechanism of the reaction**

The stoichiometry of the reaction between ACM and Pd (II) has been determined spectrophotometrically by applying Job’s continuous variation method (44), the plot (Fig. 9) reached a maximum value at a mole fraction of 0.6 which indicated the formation of a 2:1 ACM-Pd(II) complex; pointing out that two molecules of the drug react with one molecule of Pd (II). The drug reacts via its sulfur and nitrogen atoms with Pd (II) ion. Based on the obtained molar reactivity and by analogy to a previous study (38), the reaction pathway is proposed to proceed as shown in Fig. 10.

**CONCLUSION**

It is found that ACM and Pd (II) can form a yellow coloured complex. A simple and sensitive method was developed for the determination of acetazolamide in pure form and in its tablet. It can measure as low as 2.96 \( \mu\)g/ml with good accuracy. The complex formed did not require a prior extraction procedure. The proposed method could be used for routine quality control and it has some distinct advantages over other existing methods regarding sensitivity, time saving, and a lower detection limit (LOD) of 0.98 \( \mu\)g/ml. It is considered as a stability indicating one.

**REFERENCES**

1. Reynolds JEF Martindale. The Extra Pharmacopoeia, 32nd ed. Massachusetts: The Pharmaceutical Press. 1999; 810.
2. Eduardo EC, Fernando DS, Ricardo DE, José CP. A potentiometric and spectrophotometric study on acid–base equilibria in ethanol-aqueous solution of acetazolamide and related compounds. *Talanta*. 1999; 49: 859-868.
3. Khamis EF, Abdel-Hamid M, Hassan EM, Eshra A, et al. A stability-indicating first-derivative spectrophotometric assay of acetazolamide and its use in dissolution and kinetic studies. *J. Clin. Pharm. Ther*. 1993; 18: 97.
4. Moratal JM, Martinez-Ferrer MJ, Jimenez HR, Donaire A, et al. 1H NMR and UV-Vis spectroscopic characterization of sulfonamide complexes of nickel(II)-carbonic anhydrase. Resonance assignments based on NOE effects. *J. Inorg. Biochem*. 1992; 45: 231.
5. Alzuet G, Ferrer S, Borras J. Acetazolamide-M (II) [M (II)=Co (II),Ni (II),Cu (II)] complexes with ethylamine, diethylamine, triethylamine, and potassium hydroxide. *J. Inorg. Biochem*. 1991; 42: 79.
6. Abbine H, Elsayed MA, Elsayed YM. pH-induced difference spectrophotometric assay of acetazolamide, hydrochlorothiazide, and furosemide. *J. AOAC. Int*. 1978; 61: 695.
7. Gomez Z, Arantzazu M, Barrio RJ. Joint determination of todralazine and acetazolamide in human serum by differential pulse polarography. *J. Pharm. Biomed. Anal*. 1994; 12: 883.
8. Fogg AG, Ghawji AB. Reductive amperometric determination of nitrofurantoin and acetazolamide at a sessile mercury drop electrode using flow injection analysis. *Anal*. 1988; 113: 727.
9. Haesslein A, Hacker MC, Mikos AG. Effect of macromer molecular weight on in vitro ophthalmic drug release from photo-crosslinked

![Figure 9. Continuous variation graph for acetazolamide and Pd (II) (5.0 \( \times \) 10\(^{-3}\) M for each of ACM and Pd (II)).](image1)

![Figure 10. Proposal of the reaction pathway between ACM and Pd (II).](image2)
matrices. *Acta. Bio.* 2008; 4: 1-10.
10. Zarghi A, Shafaei A. Rapid determination of acetazolamide in human plasma. *J. Pharm. Biomed. Anal.* 2002; 28: 196.
11. Ichikawa N, Naora K, Hirano H, Iwamoto K. Quantitation of acetazolamide in rat plasma, brain tissue and cerebrospinal fluid by high-performance liquid chromatography. *J. Pharm. Biomed. Anal.* 1998; 17: 1415.
12. Allen LV, Erickson MA 3rd. Stability of acetazolamide, allopurinol, azathioprine, clonazepam, and fluvoxamine in extemporaneously compounded oral liquids. *Am. J. Health Syst. Pharm.* 1996; 53: 1944-1949.
13. Ohta T, Takamiya I, Takitani S. Carbonic anhydrase-immobilized pre-column for selective on-line sample pretreatment in high-performance liquid chromatographic determination of certain sulfonamide drugs. *Biomed. Chromatogr.* 1994; 8: 184-188.
14. Campins FP, Herrera HR, Sevillano CA. Application of column-switching techniques to the determination of medium polarity drugs: determination of acetazolamide in urine. *J. Chromatogr. Biomed. Appl.* 1994; 65: 85-93.
15. Gomaa ZS. Determination of acetazolamide in dosage forms by high performance liquid chromatography. *Biomed. Chromatogr.* 1993; 7: 134.
16. Bonet Domingo E, Medina Hernández MJ, Ramis Ramos G, García Alvarez-Coque MC. High-performance liquid chromatographic determination of diuretics in urine by micellar liquid chromatography. *J. Chromatogr.* 1992; 582: 189.
17. Herrera-Hernández R, Campins-Falcó P, Sevillano-Cabeza A. Determination of acetazolamide in human urine samples by reverse-phase high-performance liquid chromatography in the presence of xanthenes. *J. Chromatogr.* 1992; 582: 181.
18. Alexander KS, Haribhakti RP, Parker GA. Stability of acetazolamide in suspension compounded from tablets. *J. Hosp. Pharm.* 1991; 48: 1241.
19. Tsai FY, Lui LF, Chang B. Analysis of diuretic doping agents by HPLC screening and GC-MSD confirmation. *J. Pharm. Biomed. Anal.* 1991; 9: 1069-1076.
20. Coper SF, Masse R, Dugal R. Comprehensive screening procedure for diuretics in urine by high-performance liquid chromatography. *J. Chromatogr.* 1989; 489: 65.
21. Le Bars D, Luthra SK, Pike VW, Swenson ER. The radiosynthesis of a 11C-labelled carbonic anhydrase inhibitor-[carbonyl-11C]acetazolamide. *Int. J. of Rad. Appl. and Instrum. Part A.* 1988; 39: 671-675.
22. Hartley R, Lucock M, Becker M, Smith JJ, et al. Solid-phase extraction of acetazolamide from biological fluids and subsequent analysis by high-performance liquid chromatography. *J. Chromatogr.* 1986; 377: 295.
23. Chapron DJ, White LB. Determination of acetazolamide in biological fluids by reverse-phase high-performance liquid chromatography. *J. Pharm. Sci.* 1984; 73: 985.
24. Chambers DM, White MH, Kostenbauder HB. Efficient extraction and reversed-phase high-performance liquid chromatography-ultraviolet quantitation of acetazolamide in serum. *J. Chromatogr.* 1981; 225: 231.
25. Gal J, Ellis PP, Rendi M. Determination of acetazolamide in biological fluids by high-performance liquid chromatography. *Curr. Eye Res.* 1981; 1: 361.
26. Hossie RD, Mousseau N, Sved S, Brien R. Quantitation of acetazolamide in plasma by high-performance liquid chromatography. *J. Pharm. Sci.* 1980; 69: 348.
27. Bayne WF, Rogers G, Crisologo N. Assay for acetazolamide in plasma. *J. Pharm. Sci.* 1975; 64: 402.
28. The British Pharmacopoeia. *London: The Stationary Office.* 2008.
29. United States Pharmacopoeia XXX, the National Formulary XXV. *Rockville, MD: United States pharmacopoeial convention.* 2008. Electronic Version.
30. Parasrampuria J, Brittain HG (Ed). *Analytical Profiles of Drug Substances and Excipients.* New York: Academic Press, 1993; 22.
31. Jovanovic T, Stanovic B, Koricanac Z. Spectrophotometric investigation on complex formation of captopril with palladium (II) and its analytical application. *J. Pharm. Biomed. Anal.* 1995; 13: 213-217.
32. El-Enany N. Spectrophotometric determination of glitazone in pharmaceuticals and biological fluids through ternary complex formation with eosin and palladium (II). *Il. Farmaco.* 2004; 59: 63-69.
33. El-Walily AFM, Gazy AA, Belal SF, Khamis EF. Quantitative determination of some thiazole cephalosporins through complexation with palladium (II) chloride. *J. Pharm. Biomed. Anal.* 2000; 22: 385-392.
34. El-Walily AM, Belal SF, Bakry RS. Spectrophotometric and spectrofluorimetric estimation of ciprofloxacin and norfloxacin by ternary complex formation with eosin and palladium (II). *J. Pharm. Biomed. Anal.* 1996; 14: 561-569.
35. Jiao GS, Loutet A, Lee HB, Kalinin S, et al. Syntheses and spectroscopic properties of energy transfer systems based on squaraines. *Tetrahedron.* 2003; 59: 3109-3116.
36. Gowda HS Jayaram. Complexes of palladium (II) with phenothiazines. *J. less Comm. Met.* 1980; 72: 37-42.
37. Gowda NMM, Vallabhaheni RK, Gajula I, Ananda S. Palladium (II)-phenothiazine complexes: synthesis and characterization. *J. Mol. Str.* 1997; 407: 125-130.
38. Bakry RS, Razak OA, Waliliy AFM, Belal SF. Spectrophotometric investigation of the formed chelate between timonacic and palladium (II) and its analytical applications. *J. Pharm. Biomed. Anal.* 1998; 17: 95-101.
39. El-Enany N, Belal F, Rizk M. Spectrophotometric determination of thioctic acid in its dosage forms through complex formation with Pd (II). *J. Chin. Chem. Soc.* 2007; 54: 1-8.
40. Cotton FA, Wilkinson G. *Basic Inorganic Chemistry.* New York: *Wiley.* 1976; 436.
41. Guidance for industry; Q2B of analytical procedure: Methodology. *International Conference on Harmonization*(ICH), November 1996. http://www.fda.gov/eder/guidance/1320fnl.
42. Miller JC, Miller JN. *Statistics for analytical chemistry.* New York: Wiley, 5th edition. 2005; 256.
43. Inczedy J. *Analytical and Application of Complex Equilibria* John Wiley and Sons Inc. *Buda Pest.* 1976; 101.
44. Sawyer DT, Heineman WR, Beebe JM. *Chemistry Experiments For Instrumental Methods.* New York: *Wiley.* 1984; 198-200.